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Abstract
Background: Cardiovascular disorders associated with endothelial dysfunction, such as atherosclerosis, have decreased
nitric oxide (NO) bioavailability. Arginase in the vasculature can compete with eNOS for L-arginine and has been implicated
in atherosclerosis. The aim of this study was to evaluate the effect of endothelial-specific elevation of arginase II expression
on endothelial function and the development of atherosclerosis.
Methodology/Principal Findings: Transgenic mice on a C57BL/6 background with endothelial-specific overexpression of
human arginase II (hArgII) gene under the control of the Tie2 promoter were produced. The hArgII mice had elevated tissue
arginase activity except in liver and in resident peritoneal macrophages, confirming endothelial specificity of the transgene.
Using small-vessel myography, aorta from these mice exhibited endothelial dysfunction when compared to their non-
transgenic littermate controls. The blood pressure of the hArgII mice was 17% higher than their littermate controls and,
when crossed with apoE 2/2 mice, hArgII mice had increased aortic atherosclerotic lesions.
Conclusion: We conclude that overexpression of arginase II in the endothelium is detrimental to the cardiovascular system.
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Introduction
Arginase, a critical hepatic enzyme in the urea cycle, catalyses
the conversion of L-arginine to urea and ornithine. It exists in two
isoforms: arginase I in the cytoplasm and arginase II in the
mitochondria. In general, vascular arginase is thought to compete
with endothelial nitric oxide synthase (eNOS) for L-arginine. As
such, upregulation of arginase activity and expression has been
reported to play a role in various vascular pathologies, such as
pulmonary hypertension associated with sickle cell disease [1],
primary pulmonary arterial hypertension, [2] ischemia-reperfu-
sion, [3] uremia, [4] as well as various animal models of arterial
hypertension, [5] aging, [6] sexual arousal, [7,8] diabetes [9] and
atherosclerosis [10,11,12].
The first indication that arginase may play a role in
atherogenesis came from reports that apoE 2/2 mice fed a high
fat diet have increased aortic arginase activity and that inhibition
of arginase resulted in reduced plaque size [11]. In addition, the
proatherogenic oxidized low density lipoproteins have been
reported to stimulate arginase II activity and attenuate NO
production in human endothelial cells [12]. More recently, studies
examining the effect of high fat and high cholesterol diets on
systemic L-arginine bioavailability and arginase activity suggest
that arginase may in fact contribute to the initiation of
atherosclerosis [13]. Conversely, increased levels of arginase I in
macrophages have been linked with atheroprotection [14] and
regression of atherosclerotic plaques [15].
To date, a lack of selective pharmacological inhibitors has
hindered investigations into the role of the specific arginase
isoforms in blood vessel pathophysiology. Although several
arginase inhibitors exist, including NG-hydroxy-L-arginine (L-
NOHA), Nv-hydroxy-nor-arginine (nor-NOHA), L-valine, nor-
valine, a-difluoromethylornithine (a-DFMO), (S)-(2-boronoethyl)-
L-cysteine-HCl (BEC) and 2(s)-amino-6-boronohexanoic acid
(ABH) [16,17], none of these distinguish between arginases I
and II. Furthermore, the use of many of these compounds is
severely limited in functional vascular studies due to their
vasodilator properties [18], such that blockade of more than just
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arginase is apparent. Given these limitations, genetic manipulation
techniques offer an alternative way to examine the contributory
roles of arginase I and II in vascular function. Mice globally
lacking arginase I do not survive beyond 10–14 days post-birth due
to the systemic build-up of toxic ammonia [19]. Arginase II-
deficient mice, on the other hand, have lifespan identical to their
WT controls but were found unexpectedly to have hypertension, a
phenotype that misaligns with their dampened local vasoconstric-
tory profile and thus limits the usefulness of this model in
cardiovascular studies [20]. To overcome these limitations,
transgenic mice with endothelial cell specific overexpression of
arginase II were generated. Here, we report on the role of arginase
II on endothelial function, blood pressure and in the pathogenesis
of atherosclerosis.
Methods
Creation of hArgII Mice and Crossbreeding with
apoE 2/2
The study protocol was approved by the by the Animal Care
and Use Committee of the NHLBI (#H-0050R1) and by Alfred
Medical Research and Education Precinct (AMREP) Animal
Ethics Committee (#E/0710/2008/B), which adheres to the
National Health and Medical Research Council (NHMRC) of
Australia Code of Practice for the Care and Use of Animals for
Scientific Purposes.
The full-length hArgII (2 kb) cDNA flanked by Not I linkers was
inserted into the unique Not I cloning site of the endothelial
specific expression vector pSPTg.T2FpAXK [21,22] (kindly
provided by Dr. Thomas N. Sato; The University of Texas,
Southwestern Medical Center at Dallas, TX). The vector has
2.1 kb of the mouse Tie2 promoter, SV40 polyA signal and a
1.6 kb Tie2 enhancer. Correctly oriented plasmids were digested
with Sal I, and DNA fragments containing the Tie2 promoter,
hArgII cDNA, the SV40 polyA signal and Tie2 enhancer were
isolated by preparative electrophoresis in 0.8% agarose gel and
Zymoclean gel DNA recovery kit. The DNA fragments were
additionally purified by ultracentrifugation in a CsCl gradient in a
Beckman TL-100 table top ultracentrifuge at 95000 RPM for
24 hrs at 20uC and dialyzed against 10 mM Tris-HCl, pH 7.4,
0.1 mM EDTA. Microinjections were performed into the
pronuclei of fertilized eggs from C57BL/6J females (Jackson
Laboratory, ME, USA). The transgenes were transferred on to the
apoE2/2 background by crossing carriers of the hArgII with
apoE2/2 mice on the C57Bl/6J background (Jackson Labora-
tory, Stock Number 002052).
All mice were fed ad libitum a standard rodent autoclaved chow
diet containing 4% fat and 50 mg cholesterol (NIH31 normal
chow diet; Zeigler Brothers Inc., Gardners, Pennsylvania, USA).
Both male and female transgenic mice (aged 3–8 months) and
their WT littermate controls were used in this study.
PCR Genotyping of Mouse Colonies
For genotyping, DNA was isolated from tail clips and analyzed
by real-time quantitative PCR (qPCR) on an ABI7300 or
ABI7900HT, using primers specific for hArgII or m18sRNA
(ABI TaqMan MGB assays Hs00968978_m1 and
Hs00982837_m1). DNA isolated for injections was used to make
calibration curves. The following standard conditions were used
during qPCR: volume of reagent mix, 20 ml for ABI7900HT and
25 ml for ABI7300, concentration of DNA in wells was 0.2 ng/ul.
ABI TaqMan Universal PCR Master Mix, No AmpErase UNG,
Cat# 4324018 was used. The final concentration of primers was
900 nM, TaqMan MGB probe 2250 nM. The manufacturer’s
thermal cycler protocol (95 C for 10 min, followed by 40 cycles at
95uC for 15 s, 60uC for 1 min) was used.
Western Blot Analysis
Kidney, heart and aortic lysates were obtained by homogeni-
zation in a glass homogenizer in cold lysis buffer then centrifuged
at 130006g for 10 mins to removed unlysed cell bodies. Western
blot analysis was done as described previously, [23] using 6, 8 or
12% acrylamide gels for eNOS monomer:dimer, arginase II and
eNOS/iNOS, respectively. Twenty (eNOS monomer:dimer), fifty
(eNOS/iNOS) or one hundred (arginase) mg of protein were
loaded per lane. Rabbit polyclonal arginase II antibody cross
reactive to mouse (Santa Cruz; 1:3000), mouse monoclonal eNOS
or iNOS antibody (BD Biosciences; 1:2500) were utilized. A goat
anti-rabbit (for arginase II) and a goat anti-mouse (for eNOS/
iNOS) IgG-HRP secondary antibody (Bio-Rad, 1:3000 dilution,
one hour incubation) were used for detection. The eNOS
monomer:dimer ratio was determined using low-temperature
SDS-PAGE (LT-PAGE) where gels and buffers were kept at
4uC prior to and during electrophoresis. Following LT-PAGE, gels
were transferred on to a PVDF membrane at 4uC and the blots
were probed as routine western blots for eNOS monomer and
dimer (both BD Transduction; 1:10,000) [24]. To ensure equal
loading, blots were probed with b-tubulin antibody (Santa Cruz
1:1000). Bands of interest were visualized using SuperSignal West
Pico reagent (Pierce, Rockford, IL). Immunoreactive bands were
quantified by densitometry using image J (version 1.42q).
Expression Analysis with Real-time Quantitative RT-PCR
Tissue samples were preserved in RNAlater (Invitrogen, Cat.
No. AM7020) until RNA isolation, using TRIzol Reagent
(Invitrogen, Cat. No. 15596-026). Isolated RNA (2 mg) was treated
with DNAse (Promega) and then reverse transcribed into cDNA
using ABI TaqMan Reverse Transcriptase Reagents Kit (Cat. No.
N808-0234). 40 or 50 ng cDNA was used for per qPCR reaction.
PCR reaction, either TaqMan (Table 1) or SYBR Green assay
(Fig. 1), was respectively performedon the ABI7300 or
ABI7900HT. Primers and probes for Taqman reaction were
obtained either from ABI kits or designed by using ABI Primer
Express 3.0 software, while primers for SYBR Green were
designed using Roche’s ProbeFinder software and synthesized by
Sigma. All sequences are available upon request. Two methods to
calculate expression levels were used. For Taqman assay he
relative expressions of hArgII, as well as of other genes, were
calculated against the expression of mouse arginase II gene in the
kidney of non-transgenic mice. Expression of mouse iNOS and
eNOS, measured by SYBR Green assay, were calculated by
comparative CT (DDCT) method with 18sRNA used for normal-
ization.
Analyses of Plasma Lipid, Lipoproteins and L-arginine
Metabolites
Total cholesterol, triglycerides, phospholipids, and free choles-
terol in EDTA-plasma were quantified after a 4-hour fast, using
enzymatic kits as previously described [25]. HDL cholesterol
(HDL-C) was determined as the cholesterol remaining in plasma
after precipitation of apoB-containing lipoproteins with Raichem
HDL-Cholesterol reagent (cat. No. 82051). Plasma concentrations
of L-arginine and its metabolites, citrulline, NG-hydroxy-L-
arginine (NOHA), asymmetric dimethylarginine (ADMA), sym-
metric dimethylarginine (SMDA), and ornithine were determined
by high-performance liquid chromatography (HPLC), as previ-
ously described [26].
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Mouse Peritoneal Macrophages
Resident peritoneal macrophages were obtained by peritoneal
lavage [27] with 10 ml of sterile PBS without Ca2+ and Mg2+
containing 50 mg/ml of heparin. Cells from 10 mice were placed
into 5 wells of 6-well tissue culture plates and allowed to adhere for
1.5 hr in serum-free DMEM or RPMI-1640, after which non-
adherent cells were removed by rinsing the cells with PBS without
Ca2+ and Mg2+. Adherent cells were directly used for RNA
isolation.
Arginase Activity Assay
Arginase activity in cell or tissue lysates was measured by the
conversion of [14C-guanidino]-L-arginine to [14C]urea, which was
converted to 14CO2 by urease and trapped as Na2
14CO3 for
scintillation counting [28,29]. Arginase activity was expressed as
nmoles urea formed per min per mg of protein at 37uC. The assay
represents the sum of the activities when both arginase I and
arginase II isozymes are present.
Purification of Lung Endothelial Cells
Lung endothelial cells were isolated by an immunomagnetic
isolation method, as previously described [30]. Only one round of
selection was performed in which Dynabeads Sheep anti-Rat IgG
(Invitrogen, catalogue number 110.35) coated with rat anti-mouse
CD31 (PECAM-1, clone MEC13.3) antibody (Pharmingen Cat.
No. 553369) were used, which resulted in EC rich and EC
depleted fractions. After isolation adherent and non-adherent cells
were homogenized in cell lysis solution [28] and the protein
extracts obtained were used for analysis of arginase activity.
Table 1. Expression of hArgII, mArgI and mArgII mRNAs in
tissues of female C57Bl/6NT and hArgII transgenic mice.
Mice Gene Relative expression (%)
Aorta Heart Kidney Liver Lung
hArgII
transgenic
hArgII 8596163 17416450 5506160 106624 10866247
WT mArgII 0.260.05 0.360.03 10067.9 1.260.6 11.262.5
hArgII Tg 0.160.01 0.160.05 150.3650.7 2.561.4 12.160.5
Difference
(p)
NS NS NS NS NS
WT mArgI 3.663.3 7.965.5 1.260.9 53206254 11.263.1
hArgII Tg 2.761.2 1.660.6 1.460.6 62246597 30.2618.6
Difference
(p)
NS NS NS NS NS
Expression of hArgII, mArgI and mArgII in five tissues (aorta, heart, kidney, liver
and lung) of heterozygous Line 4 hArgII mice (n = 3) and C57Bl/6NTac (n = 3). All
data were presented as percent relative to expression of mArgII in normal
kidney, which was assigned as 100%. Values are given as mean 6 SEM and
compared using Student’s t-test where NS represents not significant.
doi:10.1371/journal.pone.0039487.t001
Figure 1. Representative western blot analysis of arginase II in A kidney, heart and aorta of male homozygous Line 11 hArgII mice
(TG) and their WT littermate controls. Expression analysis of B eNOS and C iNOS using real-time quantitative RT-PCR and protein expression of
D eNOS and E iNOS and F eNOS monomer:dimer ratio in aorta from male homozygous Line 11 hArgII mice and their WT littermate controls. Data are
presented as mean 6 SEM; n= 428. Values were compared with an unpaired Student’s t-test where * = P,0.05.
doi:10.1371/journal.pone.0039487.g001
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Vascular Reactivity
Thoracic aorta and mesenteric arteries were excised and placed
into ice-cold Kreb’s modified solution (composition in mM: NaCl
119, KCl 4.7, MgSO4N7H20 1.17, NaHCO3 25, KH2PO4 1.18,
CaCl2 2.5, glucose 11 and EDTA 0.03). The adipose and
connective tissue were removed and 2 mm length segments were
mounted in the myograph. After an equilibration period of
30 min, all vessels were subjected to an oxygenated and pre-
warmed (37uC) high potassium physiological salt solution (KPSS in
mM; KCl 123, MgSO4N7H20 1.17, NaHCO3 25, KH2PO4 1.18,
CaCl2 2.5, glucose 6.05 and EDTA 0.03) to assess vessel viability.
Responses to vasodilators were then examined in arteries
preconstricted to ,50% KPSS with either cirazoline (10–
100 nmol?L-1) or 30 mM potassium salt solution (30 mM KCl,
composition in mM; NaCl 84, KCl 40, MgSO4N7H20 1.17,
NaHCO3 25, KH2PO4 1.18, CaCl2 2.5, glucose 11 EDTA 0.03).
Potassium was chosen for mesenteric arteries because at the
concentration used, any effect of EDHF would be negated,
unmasking the contribution of NO to vasodilatation [31]. All
vasorelaxation responses were expressed as percent relaxation
from the preconstriction response. Variable slope sigmoidal
concentration response curves to each agonist were fitted and
graphed, and the -log EC50 M value, (i.e. the concentration giving
50% of the maximum response) was calculated for individual
curves using GraphPad Prism (v 5.0). Rmax depicts the maximum
relaxation response obtained.
Measurement of Aortic NO Levels
NO was measured in aortas by measuring total nitrate and
nitrite (NOx) levels using the Griess reaction method according to
a kit (Cayman Chemical) as previously described [32]. Briefly,
aortas were homogenized in phosphate buffered saline (PBS)
pH 7.4 and the homogenate filtered using a 10 kDa Amicon filter.
Aortic homogenates were incubated with nitrate reductase enzyme
and enzyme cofactor mixture for 3 hours at room temperature.
Griess reagent 1 and 2 were added to the homogenates and left to
incubate at room temperature for 10 mins. Absorbance was read
at 540 nm and the concentrations of NO were calculated from a
standard curve and normalized to protein concentration.
Measurement of Aortic Superoxide Level
Superoxide formation was measured using both L-012 en-
hanced chemiluminescence and dihydroethidium (DHE; 2 mM)
staining [33,34]. Thoracic aorta from 10–15 week old WT and
hArgII transgenic mice were isolated and placed in ice-cold Krebs-
HEPES solution and cleared of connective tissue. For the L-012
enhanced chemiluminescence, the aortae were segmented into
lengths of 3–5 mm and incubated at 37uC in the dark for 1 hour.
Background luminescence, read using a luminometer (Berthold,
LB96), was subtracted from an average of 10 readings and
normalized to dry weight. Each measurement was expressed as
relative light units per second per mg of protein (RLU.-
sec21.mg21). For the DHE staining, tissues were immersed in
Tissue-Tek as previously described [34] and snap frozen in liquid
nitrogen and stored at 280uC until they were cryocut into 30 mM
thick sections and mounted onto slides (Menzel-Glaser SuperFrost
Plus). A Zeiss 510 Meta confocal microscope equipped with a
krypton/argon laser was used to image the fluorescence of 2-
hydroxyethidium, the specific product of the reaction. The laser
settings were identical for each image acquired, excitation and
emission spectra of 488 and 543 nm, respectively. The intensity of
the fluorescence was quantified in three consecutive segments from
the same aorta using Image J (version 1.42q) and the values
averaged.
Blood Pressure Determination
Mice were anesthetized with xylazine (6 mg/kg body wt i.p.)
and ketamine chloride (120 mg/kg body wt i.p.) and placed in a
supine position for measurement of blood pressures (systolic,
diastolic and mean arterial) via a Millar-solid state pressure
catheter (SPR-671, Millar Instruments Inc.) surgically inserted
through the right carotid artery. Anesthesia and core body
temperature (36.5–37 degrees Celsius) were maintained for the
duration of the experiment. Only stable blood pressure data were
included. Data was collected and analysed using Chart 5 Pro (ADI
Instruments).
Atherosclerotic Lesion Assessment
For evaluation of the development of atherosclerosis in
experimental and control animals, we used en face measurements
of the surface of mouse aortas covered by lipid deposits, as
previously described [35] with aortas stained by Sudan IV.
Quantification of plaques of each animal was performed in a blind
fashion, using Image-Pro Plus version 4.1 software (Media
Cybernetics, Inc., MD).
Data Analysis and Statistics
Unless otherwise indicated, all data are presented as mean 6
standard error of the mean (SEM). Results were analysed by
Student t-test (paired or unpaired, as appropriate). Where three
values were compared, comparisons were made using one-way
ANOVA with Bonferroni posthoc analysis. Statistical analysis was




Two different founders of hArgII transgenic mice were
generated: line 4, containing 120 copies of the transgene, and
line 11 containing 60 copies in the heterozygous state, as
determined by real-time qPCR genotyping. Relatively high levels
of expression of hArgII transgene was found in all studied tissues
examined compared to the endogenous mArgII gene (Table 1). In
hArgII mice, the ratio hArgII to mArgII expression varied from
almost 6-fold (in kidney) to more than 4800-fold and 6700-fold in
aorta and heart, respectively. These observations were confirmed
in Western blot analysis (Fig. 1A). Overexpression of hArgII in
endothelial cells did not influence mArgI or mArgII expression
when measurements were performed with RNA isolated from
heart, kidney, liver and lung (Table 1). Both eNOS and iNOS
mRNA expression were significantly increased in aorta from
hArgII mice (P,0.05; n = 6; Fig. 1B&C) when compared to their
non-transgenic littermate wild type (WT) controls, but there was
no difference in protein expression (Fig. 1D&E; n= 4; P.0.05) nor
the eNOS:monomer: dimer ratio (Fig. 1F; n = 6; P.0.05).
Arginase Activity is Increased in hArgII Mice
The transgenic mice had elevated tissue total arginase activity
when compared to their non-transgenic siblings: 5–40 fold in
aorta, heart, kidney, lung and spleen (Fig. 2A). There was no
difference in total arginase activity in the liver in hArgII mice (Line
4, 77936568; Line 11, 919261027 vs. WT, 85106667 nmol/
mg/min; n= 325; P.0.05).
Specificity of the expression of the hArgII gene driven by the
Tie2 promoter was verified by assessing the arginase activity of
resident peritoneal macrophages and lung fractions either after
enrichment or depletion of endothelial cells. Resident peritoneal
macrophages from transgenic and control mice did not differ in
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the level of arginase activity (Fig. 2B). Furthermore, lung
endothelial cell-enriched fractions isolated from hArgII transgenic
animals had 3.760.3-fold higher arginase activity than fractions
partially depleted of lung endothelial cells (P,0.05; Fig. 2C & D).
Plasma L-arginine Metabolites and Lipid Levels are
Unchanged
To assess the effect of the hArgII transgene, plasma concentra-
tions of L-arginine and several of its metabolites were determined.
Overexpression of hArgII did not lead to significant changes in
plasma levels of L-arginine or its metabolites in transgenic mice
compared to their non-transgenic littermate controls (data not
shown). Furthermore, when the ratio of plasma arginine to the
sum of plasma ornithine plus citrulline was determined, as an
indicator of global arginine bioavailability, there were also no
differences in the available plasma arginine bioavailability ratio
(arginine/orthinine + citrulline) between strains (WT: 0.5960.06,
hArgII: 0.6460.04; P.0.05; n = 6211). Similarly, plasma lipid
profiles were unaffected in the hArgII lines (data not shown).
hArg II Overexpression Induces Endothelial Dysfunction
Maximal contractile responses to high K+ levels in aorta and
small mesenteric arteries (SMA) from hArgII mice were not
significantly different from their non-transgenic littermate controls
(Table 2; n= 728; P.0.05). Endothelial dysfunction was evident
in aortas from hArgII mice, as demonstrated by a significant shift
to the right in the endothelium-dependent vasodilator acetylcho-
line (ACh)-induced relaxation (EC50: 7.160.2 M) compared to
their non-transgenic littermate controls (EC50: 7.660.1 M;
Fig. 3A, n= 528; P,0.05). There was no significant difference
in ACh-mediated relaxation in small mesenteric arteries (SMA)
constricted with cirazoline (Fig. 3B) or with inhibition of
endothelium-dependent hyperpolarizing factor (EDHF) with a
high K+ constriction (Fig. 3B; n= 427; P = 0.06), although the
Figure 2. Arginase activities of: A heterozygous hArgII Line 4 and Line 11 mice and C57Bl/6 males (n=325) and B resident
peritoneal macrophages. Macrophage activities are mean and range for two groups each of pooled samples for male and female homozygous
hArgII mice and littermate controls (n = 4/group for WT; n = 4 or 5/group for hArgII lines 11 and 4, respectively). Arginase activity in extracts from lung
endothelial cells immunomagnetically separated to endothelial cells (EC fraction) or fractions depleted of endothelial cells (EC depleted) from C
C57Bl/6 (n = 4) and D from hArgII Line 4 mice (n = 4). Data are presented as mean 6 SEM. Values were compared A with a 1-way ANOVA with
Bonferroni posthoc test and B–D with Student’s t-test where * = P,0.05, ** = P,0.01 and *** = P,0.001.
doi:10.1371/journal.pone.0039487.g002
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latter did tend towards statistical significance. The NOS inhibitor
L-NAME (100 mM) attenuated the responses to ACh in aorta
(Fig. 3A; n= 526; P,0.001) from WT and hArgII, confirming the
NO dependency of the responses. L-NAME attenuated the
responses to ACh in WT mice preconstricted with cirazoline
and K+ (P,0.05), but there was no reduction in ACh responses
from SMA in hArgII mice, suggesting an attenuated NO-
dependent and increased EDHF-dependent response (Fig. 3B&C,
n= 426; P.0.05).
In the aorta, no differences were observed between the different
strains in responses to the endothelium-independent vasodilator
sodium nitroprusside or the vasoconstrictor noradrenaline (NA)
(Table 2; n= 528; P.0.05). Denudation of the endothelium (data
not shown) or treatment with L-NAME enhanced the constriction
to NA, although the magnitude of augmentation was similar
between all strains of mice (Table 2; n = 528; P.0.05).
Furthermore, there was significantly enhanced vasoconstriction
in SMA from hArgII mice compared to WT, which was not
affected by NOS inhibition (Table 2; n= 425; P,0.05).
Basal Aortic NO Levels are Unaffected by hArgII
Overexpression
NO production assessed by the Griess reaction showed no
differences in the production of NO in aorta of hArgII when
compared to their WT littermate controls (n = 829; P,0.01;
Fig. 3C).
ROS Levels are Unchanged in hArgII Aorta
ROS levels, assessed by both L-012-enhanced chemilumines-
cence and dihydroethidium (DHE) staining were unaltered in the
aortas of hArgII (DHE: 3299611; L-012: 192643) mice versus
their WT littermate controls (DHE: 3390668; L-012: 180640
relative light units; n = 426; P.0.05).
Blood Pressure is Increased in hArgII Mice
Arterial blood pressure, monitored by a Millar-solid state
pressure catheter surgically inserted into the right carotid artery,
indicated that hArgII mice had 17–20% increases in systolic and
mean arterial blood pressure when compared to their non-
transgenic littermate controls (n = 10; P,0.05; Fig. 4A, B).
Although not statistically significant, diastolic blood pressure
tended to be increased (P = 0.06; Fig. 4C).
Atherosclerotic Lesions in hArg/apoE 2/2 Cross are
Enhanced
In order to examine the effect of the hArgII transgene on
atherogenesis, the transgenes were transferred to mice with an
apoE 2/2 background. Insertion of the hArgII transgene did not
affect total cholesterol, triglycerides or HDL in 8-month-old
crossed hArgII/apoE 2/2 mice when compared to comparably
aged control apoE 2/2 mice (Fig. 5A, B; n= 8213; P.0.05).
Nevertheless, en face aortic lesion measurement throughout the
aorta with Sudan IV lipid staining demonstrated that 8-month-old
hArgII/apoE 2/2 females had significantly increased aortic
lesion development in both lines 4 and 11 compared to apoE2/2
sibling control females (Fig. 5C; n= 11222; P,0.05). The effect of
the transgene was dependent on the level of arginase activity in
tissues. Transgenic mice belonging to line 4, the strain exhibiting
the highest arginase activity in tissues (see Fig. 2A), had twice the
development of aortic lesions in comparison with control
(P,0.001). Some transgenic mice had greater than 70% surface
area coverage by atherosclerotic plaque (Fig. 5D), whereas apoE
2/2 mice typically only had 20% surface area coverage (Fig. 5E).
Discussion
In the current study, we show that the overexpression of the
arginase II isoform elicits hypertension and exacerbates athero-
genesis. Our results suggest that overexpression of hArg II leads to
endothelial dysfunction via a decrease in NO production and that
this contributed to hypertension and increased lesion development
in the transgenic mice.
Consistent with previous reports, [36] the Tie2 promoter drove
overexpression of the hArgII transgene in endothelial cells, as
indicated by the marked enrichment of arginase activity in isolated
lung endothelial cells (Fig. 2D). Likely dependent on the site of
integration into chromosomal DNA, the Tie2 promoter has, at
least in one case, been found to drive expression of a transgene in
myeloid cells [37]. Expression of the hArgII transgene was
therefore evaluated in peritoneal macrophages. In marked contrast
to endothelial cells, there was no overexpression of hArgII in
macrophages (Fig. 2B). The hArgII transgene did not significantly
alter the expression of the mouse endogenous genes for arginase I
and II in any of the tissues analysed (Table 1), rendering it unlikely
that the observed vascular effects resulted from changes to
endogenous arginase.
Table 2. Responses to noradrenaline (NA) and sodium nitroprusside (SNP) in the absence and presence of the NOS inhibitor L-
NAME (100 mM) in aorta and small mesenteric arteries from male homozygous Line 11 hArgII mice and their male WT littermate
controls.
Agonist KPSS NA NA + L-NAME SNP SNP + L-NAME
Aorta Emax (g) EC50 Emax (g) EC50 Emax (g) EC50 Rmax EC50 Rmax n
hArgII Tg 0.860.1 8.160.1 0.4960.1 8.560.1** 1.260.2* 8.160.2 8767 8.660.2 9861 6
WT 0.7760.1 8.160.1 0.5860.1 8.560.1** 1.360.1*** 8.360.2 9862 8.660.1 9861 5–7
SMA
hArgII Tg 0.5060.1 6.660.4 1.4660.3* 6.760.2 1.3760.3 7.560.1 9267 7.760.4 9268 4–5
WT 0.960.2 6.360.1 0.6860.1 6.360.1 0.6860.1 7.960.1 9862 7.860.4 9861 4–5
EC5O values are expressed as –log M, Emax values as the maximum response to NA in g, Rmax values as % reversal of the level of pre-contraction in response to 10 mM of
the SNP. Values are given as mean 6 SEM. n = 428 per group.
*P,0.05,
**P,0.01,
***P,0.001 vs WT control (Student’s t-test).
doi:10.1371/journal.pone.0039487.t002
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There were no significant differences between WT and the
transgenic mice in the plasma levels of L-arginine or its
metabolites, indicating that elevated endothelial arginase activities
did not have a significant impact on the circulating arginine pool.
The lack of differences in plasma L-arginine levels does not,
however, necessarily indicate that there were no decreases in
endothelial L-arginine levels in the hArgII arginase transgenic
mice. The production of NO from its substrate L-arginine is also
known to be dependent on the distribution and stimulation of
eNOS. Functional changes in eNOS activity and/or enhanced
oxidative stress, rather than reduced eNOS expression, may be
responsible for NO inactivation in atherosclerosis. Indeed,
although somewhat counterintuitive, in apoE 2/2 mice, eNOS
mRNA expression is either unchanged or even increased, [38,39]
as was observed in the hArgII mice in the present study (Fig. 1B).
This has been reported elsewhere in the literature, where increases
in arginase II [11] in endothelial cells are associated with
decreased NOS activity and NO production in the presence of
increased or unchanged expression of eNOS and iNOS, as
demonstrated in the current study. Furthermore, since the
uncoupling of eNOS from its dimeric state has been associated
with increased arginase expression and ROS production, [40] the
monomer:dimer ratio of eNOS was determined. Although
somewhat unexpected, there was no significant difference in the
ratio between the hArgII transgenics and their WT controls.
To determine the effect of endothelial overexpression of
arginase II on NO bioavailability, responses to the endothelium-
dependent vasodilator ACh were examined in aortae and small
mesenteric arteries. Overexpression of hArgII significantly re-
duced ACh-induced NO responses in aortae and inhibition of
NOS with L-NAME confirmed the NO dependence of the
response, suggesting the regulation of NO production via arginase
Figure 3. Concentration response curves to the endothelium-dependent vasodilator acetylcholine (ACh) before and after the
addition of the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (NAME; 100 mmol/L) in A aorta constricted with
cirazoline and mesenteric arteries constricted with B cirazoline or C high potassium from male homozygous hArgII Line 11 mice
(n=426) and their WT littermate controls (WT; n=526). D NO production as determined by measuring NOx (nitrate and nitrate) using the
Griess reaction in homogenized aorta and normalized to protein concentration in aorta from homozygous hArgII line 11 males and littermate non-
transgenic control males (n = 829). Data are presented as mean 6 SEM. EC50 and Emax values were compared using 1-way ANOVA with Bonferroni
posthoc test, where * = P,0.05 and *** = P,0.001.
doi:10.1371/journal.pone.0039487.g003
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II. There were no differences observed in mesenteric arteries
preconstricted with cirazoline. However, the response to ACh in
mesenteric arteries preconstricted with cirazoline, can be mediated
by both NO and EDHF. In WT mesenteric arteries constricted
with cirazoline, NOS inhibition markedly attenuated the response,
indicating that the relaxation was predominantly NO-mediated.
The lack of effect of NOS inhibition on responses in mesenteric
arteries from the hArgII mice (Fig. 3B) suggests that the response
was mediated predominantly via EDHF. Indeed, when a high
potassium solution was used to negate the EDHF response
induced by ACh, the response to NO in the hArgII mice was
negligible compared to the WT NO response (Fig. 3C) that were
‘unmasked’ by EDHF inhibition. These findings are in agreement
with others in the literature, [41,42] indicating that arginase II can
regulate NO bioavailability in endothelial cells and demonstrates
that increases in arginase II reduce endothelial function.
ROS production was measured in aortae of the transgenic mice,
and no significant difference in basal ROS production was
observed. Although increases in ROS have been reported in
atherosclerosis, wherein there is increased vascular arginase
activity, [11] some of which may be induced by NADPH
oxidase-generated ROS, [43] or uncoupled eNOS [44] the results
from the present study are aligned with the unchanged eNOS
monomer:dimer ratio findings and do not suggest a converse role
for arginase in modulating ROS production.
Decreased NO production often accompanies high blood
pressure [45,46] and increased arginase expression and activity
have been well-documented in this disease state. [5,47] Consistent
with these reports, our findings demonstrate a critical role for
arginase II in the development of hypertension.
NO protects endothelial function by reducing inflammation,
smooth muscle proliferation, leukocyte adhesion and platelet
aggregation. Endothelial dysfunction, due to decreased NO, has
been extensively reported in humans and animal models of
atherosclerosis [48]. Taken together with reports of increased
arginase activity and expression in atherosclerosis and the
decreased NO bioavailability of the hArgII transgenic mice we
explored the role of arginase in the development of atherosclerosis
in crossed hArgII transgenic mice with apoE 2/2 mice.
Overexpression of hArgII in endothelium significantly increased
aortic atherosclerotic lesion area in these mice. Lesion develop-
ment was greatest in the line 4 hArgII transgenics. Plasma lipids
from the crossed ApoE2/2 and hArg transgenics were similar to
their non-transgenic apoE 2/2 littermates, indicating a lipid-
independent effect on lesion development. Whilst ROS were
unchanged and NO bioavailability was reduced in the hArgII
transgenic mice the effect of increased hArgII transgene expression
in mice on an apoE 2/2 background warrants further
investigation. However, when noted in the context of the effects
elicited by the hArgII enzyme on endothelial function, the
apparent lipid-independent atherosclerotic lesion development
may indicate a role for endothelial eNOS interaction with hArgII
expression.
In summary, mice with endothelial-specific overexpression of
human arginase II were generated and characterized with respect
to vascular pathophysiology. Increased arginase II expression
appears to result in decreased NO bioavailability, which augments
MAP. Furthermore, when the hArgII transgenic mice were
crossed with apoE 2/2 mice, we observed increased atheroscle-
rotic plaque development. Importantly, increasing endothelial
arginase II expression, in the absence of any changes in plasma
lipid levels, is sufficient to increase plaque development, providing
strong evidence for the critical role of arginase II in the
development and progression of atherosclerosis.
Figure 4. Blood pressure of anaesthetized hArgII and non-
transgenic mice presented as box plots of A systolic blood
pressure (systolic BP), B mean arterial pressure (MAP) and C
diastolic BP. The box extends 25th percentile to the 75th percentile
with the median represented by the line within the box. Measurements
were from control non-transgenic sibling males (n = 9) versus Line 4 and
11 hArgII males (n = 9). Values were compared using unpaired Student’s
t-tests where * = P,0.05 and **P = ,0.01.
doi:10.1371/journal.pone.0039487.g004
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